deferoxamine has been researched along with Apoplexy in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 9.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 5.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " Thus, low-dose chronic administration of DFO or DFR induced a prolonged neuroprotective state independent of HIF-1 function." | 5.37 | Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. ( Rempe, DA; Zhao, Y, 2011) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 5.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 5.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "These results suggest that superoxide anions in the RVLM, which generate hydroxyl radicals, are increased in SHRSP and contribute to the neural mechanisms of hypertension in SHRSP." | 3.72 | Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. ( Hirooka, Y; Ito, K; Kimura, Y; Kishi, T; Shimokawa, H; Takeshita, A, 2004) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 1.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " Thus, low-dose chronic administration of DFO or DFR induced a prolonged neuroprotective state independent of HIF-1 function." | 1.37 | Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. ( Rempe, DA; Zhao, Y, 2011) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 1.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "The stroke was ischemic in all individuals and the first cerebrovascular event occurred before 6 years of age; 3 patients had recurrence of stroke despite prophylactic blood transfusion therapy and both cerebral hemispheres were affected in 4 patients." | 1.35 | Stroke in patients with sickle cell disease: clinical and neurological aspects. ( Ciasca, SM; Moura-Ribeiro, MV; Oliveira, CC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 2 |
| Abdul, Y | 2 |
| Chandran, R | 1 |
| Jamil, S | 2 |
| Ward, RA | 1 |
| Abdelsaid, M | 2 |
| Dong, G | 2 |
| Fagan, SC | 2 |
| Ergul, A | 2 |
| Sakamuri, SSVP | 1 |
| Sure, VN | 1 |
| Katakam, PVG | 1 |
| Sun, T | 1 |
| Zhao, YY | 1 |
| Xiao, QX | 1 |
| Wu, M | 1 |
| Luo, MY | 1 |
| Ward, R | 1 |
| Hafez, S | 1 |
| Wolf, V | 1 |
| Johnson, MH | 1 |
| DeGregorio-Rocasolano, N | 1 |
| Martí-Sistac, O | 1 |
| Ponce, J | 1 |
| Castelló-Ruiz, M | 1 |
| Millán, M | 1 |
| Guirao, V | 1 |
| García-Yébenes, I | 1 |
| Salom, JB | 1 |
| Ramos-Cabrer, P | 1 |
| Alborch, E | 1 |
| Lizasoain, I | 1 |
| Castillo, J | 1 |
| Dávalos, A | 1 |
| Gasull, T | 1 |
| Gelosa, P | 1 |
| Pignieri, A | 1 |
| Gianazza, E | 1 |
| Criniti, S | 1 |
| Guerrini, U | 1 |
| Cappellini, MD | 1 |
| Banfi, C | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Wood, JC | 2 |
| Pressel, S | 1 |
| Rogers, ZR | 1 |
| Odame, I | 1 |
| Kwiatkowski, JL | 2 |
| Lee, MT | 2 |
| Owen, WC | 1 |
| Cohen, AR | 1 |
| St Pierre, T | 1 |
| Heeney, MM | 1 |
| Schultz, WH | 1 |
| Davis, BR | 1 |
| Ware, RE | 1 |
| Hanson, LR | 1 |
| Roeytenberg, A | 1 |
| Martinez, PM | 1 |
| Coppes, VG | 1 |
| Sweet, DC | 1 |
| Rao, RJ | 1 |
| Marti, DL | 1 |
| Hoekman, JD | 1 |
| Matthews, RB | 1 |
| Frey, WH | 1 |
| Panter, SS | 1 |
| Adamkiewicz, TV | 1 |
| Abboud, MR | 1 |
| Paley, C | 1 |
| Olivieri, N | 1 |
| Kirby-Allen, M | 1 |
| Vichinsky, E | 1 |
| Casella, JF | 1 |
| Alvarez, OA | 1 |
| Barredo, JC | 1 |
| Iyer, RV | 1 |
| Kutlar, A | 1 |
| McKie, KM | 1 |
| McKie, V | 1 |
| Odo, N | 1 |
| Gee, B | 1 |
| Woods, GM | 1 |
| Coates, T | 1 |
| Wang, W | 1 |
| Adams, RJ | 1 |
| Inati, A | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Zhao, Y | 1 |
| Rempe, DA | 1 |
| Chaudhary, N | 1 |
| Gemmete, JJ | 1 |
| Thompson, BG | 1 |
| Xi, G | 1 |
| Pandey, AS | 1 |
| Kishi, T | 1 |
| Hirooka, Y | 1 |
| Kimura, Y | 1 |
| Ito, K | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Oliveira, CC | 1 |
| Ciasca, SM | 1 |
| Moura-Ribeiro, MV | 1 |
| Wayne, AS | 1 |
| Schoenike, SE | 1 |
| Pegelow, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Apoplexy
| Article | Year |
|---|---|
Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis.
Topics: Cerebral Hemorrhage; Deferoxamine; Hematoma; Humans; Siderophores; Stroke | 2023 |
3 trials available for deferoxamine and Apoplexy
11 other studies available for deferoxamine and Apoplexy
| Article | Year |
|---|---|
Deferoxamine prevents poststroke memory impairment in female diabetic rats: potential links to hemorrhagic transformation and ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Female; Ferroptosis; Hemin; Male; Rats; Stro | 2023 |
Iron chelation therapy to prevent poststroke cognitive impairments: role of diabetes and sex.
Topics: Animals; Chelation Therapy; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, Experimental; Fe | 2023 |
Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells | 2021 |
Altered iron homeostasis in an animal model of hypertensive nephropathy: stroke-prone rats.
Topics: Animals; Blood Pressure; Deferoxamine; Disease Models, Animal; Hemolysis; Homeostasis; Hypertension, | 2013 |
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Brain; Brain Ischemia; Deferoxamine; Dose-Res | 2009 |
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2010 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Def | 2011 |
Iron--potential therapeutic target in hemorrhagic stroke.
Topics: Cerebral Hemorrhage; Deferoxamine; Humans; Iron; Iron Chelating Agents; Nerve Degeneration; Stroke | 2013 |
Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; Blood Pressure; Brain Chemistry; Ca | 2004 |
Stroke in patients with sickle cell disease: clinical and neurological aspects.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferoxamine; Female; Humans; Inte | 2008 |
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Deferoxamine; Erythrocyte Transfusion | 2000 |